You are here: Industry Insights > Alzheimer

News List

ProMIS Neurosciences Candidate for Alzheimer's Shows Potential for Improved Therapeutic Potency americanpharmaceuticalreview
January 24, 2018
ProMIS Neurosciences has announce its lead product candidate for AD, PMN310, compared to aducanumab showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta in brain extract from eight confirmed AD brains.
New project examining FDA-approved drugs for Alzheimer’s, worries over research remains pharmafile
January 11, 2018
It’s been a gloomy period for research into Alzheimer’s disease treatments in the last week, Pfizer announced it would be shuttering its neuroscience division and Axovant’s drug candidate tanked.
Pfizer to Cut 300 Jobs as It Ends Alzheimer's, Parkinson's Quest biospace
January 09, 2018
Pfizer announced Saturday, Jan. 6, that it was abandoning research and development into new neuroscience development, including Alzheimer’s and Parkinson’s disease.
Drug for diabetes type 2 shows potential in treating Alzheimer’s biospectrumasia
January 05, 2018
The drug could also enhance levels of a brain growth factor which protects nerve cell functioning, and slows down the rate of nerve cell loss, among other benefits.
India Globalization Capital Reports Promising Spatial Memory Results in Alzheimer’s Study biospace
January 03, 2018
India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vivo data compiled from genetically engineered mice to mimic Alzheimer’s shows marked improvement in spatial memory.
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint biospectrumasia
December 26, 2017
Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in patients with prodromal or mild Alzheimer’s disease (collectively known as early Alzheimer’s disease) and with positive biomarkers for brain amyloid pathology
3 Hottest Areas of Drug Development to Keep an Eye on in 2018 biospace
December 21, 2017
Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.
Second Phase 3 Study Results for LMTX® Published in the Journal of Alzheimer's Disease prnasia
November 27, 2017
TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.
Banner Alzheimer's Institute, Novartis, and Amgen Expand Collaboration in Pioneering Alzheimer's Pre biospectrumasia
November 09, 2017
The API Generation Program is the first to incorporate both genetic testing and counselling in addition to amyloid disclosure education into the study screening process.
Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials fiercebiotech
November 03, 2017
We’ve seen it time and time again over the past 15 years from a particularly cruel disease that robs people of their memories and eventually kills them.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page